Apoptosis Pathway: Death Receptor, Mitochondrial and Granzyme Routes

Apoptosis is not one pathway but three routes into the same execution machinery. A death ligand at the surface, a mitochondrion that loses outer-membrane integrity, and a granzyme delivered by a cytotoxic lymphocyte all end at the same place: caspase-3 cleaving hundreds of cellular substrates in an orderly sequence. What differs is the entry point, the brakes that must be removed first, and — critically for anyone designing an experiment — which readout will actually report that the decision has been made.

The extrinsic arm: death ligands and the DISC

Three ligand–receptor pairs open the extrinsic route: FasL on Fas (CD95), TNF-α on TNFR1, and TRAIL on DR4 and DR5. Trimerised receptors expose cytoplasmic death domains that recruit FADD directly (Fas, DR4, DR5) or through TRADD (TNFR1). FADD's death effector domain then nucleates a filament of pro-caspase-8 and pro-caspase-10. Activation here is driven by forced dimerisation, not by cleavage — self-processing follows and stabilises the active enzyme rather than creating it.

The dial on that filament is c-FLIP. Its long isoform heterodimerises with caspase-8 to give a partially active enzyme that cleaves local substrates such as RIPK1 but is never fully processed and released; the short isoforms are purely inhibitory. Because c-FLIP is a short-lived NF-κB target gene, the signal that assembles the DISC also stocks its inhibitor. This dose-dependence, not receptor loss, explains most TRAIL resistance.

TNFR1 complex I and the necroptosis exit

TNFR1 is the exception among death receptors: its default output is survival. TRADD recruits TRAF2 with cIAP1 and cIAP2, which decorate RIPK1 with K63- and M1-linked ubiquitin. That scaffold activates NF-κB, which transcribes c-FLIP, Bcl-xL, Survivin and more cIAP2. TNF-α therefore kills only when this arm is disabled — the reason in vitro TNF cytotoxicity assays almost always need cycloheximide or a SMAC mimetic alongside the cytokine.

Strip the ubiquitin, or remove the cIAPs, and RIPK1 leaves the membrane to form a cytosolic complex II with FADD and caspase-8. If caspase-8 is also inhibited, RIPK1 instead recruits RIPK3 through their RHIM domains, and the necrosome phosphorylates MLKL, which oligomerises and ruptures the plasma membrane. Part of caspase-8's routine job is cleaving RIPK1 and RIPK3 to prevent exactly this: caspase-8-null embryonic lethality is rescued by deleting Ripk3 or Mlkl.

The intrinsic arm: BH3-only sensors and the Bcl-2 rheostat

Inside the cell, Bcl-2, Bcl-xL and Mcl-1 hold the pore-forming effectors BAX and BAK in check. BOK is a third effector, constitutively active and restrained mainly by ER-associated degradation rather than by Bcl-2 binding. Stress is transduced by the BH3-only proteins: Bim, Bad, Puma, Noxa and Bid. p53 induces Puma, Noxa and BAX transcriptionally, while AKT phosphorylates Bad and parks it on 14-3-3.

Binding is selective, and the selectivity is the clinically useful part. Bim and Puma engage every anti-apoptotic protein; Bad binds Bcl-2 and Bcl-xL but not Mcl-1; Noxa binds Mcl-1 almost exclusively. That is why venetoclax-class agents work in Bcl-2-dependent tumours and why Mcl-1 upregulation is the commonest escape. Once BAX and BAK oligomerise they form macropores; cytochrome c binds APAF1, which heptamerises into the apoptosome and activates caspase-9. Caspase-8 reaches this arm by cleaving Bid to tBid — the loop type II cells such as hepatocytes depend on absolutely.

IAPs, SMAC and the executioner caspases

The IAP family is routinely described as a single block of caspase inhibitors, and that is wrong in a way that matters experimentally. XIAP is the only mammalian IAP that inhibits caspases directly, using its BIR2 region against caspase-3 and caspase-7 and BIR3 against caspase-9. cIAP1 and cIAP2 are E3 ligases that act upstream at the receptor complex, and Survivin functions mostly within the chromosomal passenger complex during mitosis.

Mitochondria answer XIAP directly. SMAC/DIABLO and HtrA2/Omi exit alongside cytochrome c and expose IAP-binding motifs that displace XIAP from the caspases; HtrA2 additionally degrades it. Freed caspase-3 and caspase-7 cleave PARP1 to its diagnostic 89 kDa fragment and cut ICAD/DFF45, releasing CAD/DFF40 to generate the internucleosomal ladder TUNEL detects. AIF and EndoG bypass caspases altogether, producing ~50 kb fragmentation without laddering — the usual explanation when a pan-caspase inhibitor abolishes PARP cleavage yet fails to restore clonogenic survival.

The granule route and where the pathway is drugged

Cytotoxic lymphocytes use a third entry point. Perforin delivers granzyme B into the target cytosol, where it cleaves Bid at its own site and processes caspase-3 directly, skipping the receptor and adaptor layer entirely. XIAP is the dominant brake on granzyme killing, so efficiency still depends on SMAC release — worth remembering when a tumour line resists CTL or CAR-T killing despite normal antigen presentation.

Therapeutically the pathway is attacked at its brakes, not its triggers: BH3 mimetics against Bcl-2 and Mcl-1, SMAC mimetics that trigger cIAP1/cIAP2 autodegradation and convert TNF-α into a death signal, and DR4/DR5 agonists. Resistance concentrates in the same nodes — p53 loss, Mcl-1 amplification, high XIAP and Survivin — which is why they are worth quantifying rather than assuming.

Key targets and matching reagents

Studying apoptosis in vivo

Worth being direct about what is available here. Almost every node in this map is intracellular, so the reagent set behind the diagram is overwhelmingly ELISA kits and research antibodies, with one functional-grade In Vivo antibody — anti-TNF-α. In practice you perturb apoptosis genetically or pharmacologically and then measure it. Three quantitative readouts carry the weight, each answering a different question.

1. Caspase activity: has execution actually happened?

The first question is whether the executioner arm fired. Quantify caspase-3 and caspase-7 in tissue lysate and pair them with substrate cleavage — PARP1 and the ICAD/DFF45–CAD pair — because active enzyme without substrate turnover usually means the sample was taken too early. Adding caspase-8 and caspase-10 alongside caspase-9 separates a death-receptor input from an apoptosome-driven one, which caspase-3 alone can never do.

2. MOMP: cytochrome c, SMAC and the caspase-independent effectors

Mitochondrial release is the commitment step, and it is measurable. Fractionate and quantify cytosolic cytochrome c with SMAC/DIABLO and HtrA2; APAF1 reports whether the apoptosome scaffold is present. Where a caspase inhibitor fails to rescue viability, add AIF and EndoG. Reading all of these against XIAP and Survivin converts a yes/no result into an estimate of how much IAP the cell had to overcome.

3. The Bcl-2 family ratio, and the inputs you can still block

Apoptotic threshold is a ratio, not a level. Measure Bcl-2, Bcl-xL and Mcl-1 against BAX, BAK and BOK, with the sensors Bim, Bad, Puma, Noxa and Bid and their regulators p53 and AKT. Only at the surface do you keep functional leverage: anti-TNF-α is low-endotoxin In Vivo grade, while Fas, FasL, TRAIL, DR4, DR5, perforin, granzyme B, RIPK1, RIPK3 and MLKL are quantified rather than blocked. The wider In Vivo range covers the immune inputs driving them.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.